

# CITATION REPORT

List of articles citing

Cost-effectiveness of umeclidinium compared with tiotropium and glycopyrronium as monotherapy for chronic obstructive pulmonary disease: a UK perspective

DOI: 10.1186/s12962-018-0101-3

Cost Effectiveness and Resource Allocation, 2018, 16, 17.

**Source:** <https://exaly.com/paper-pdf/71559155/citation-report.pdf>

**Version:** 2024-04-10

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
4	Umeclidinium cost effective for COPD in UK. <i>PharmacoEconomics &amp; Outcomes News</i> , <b>2018</b> , 804, 36-36	0.1	
3	Cost-Effectiveness Analysis of a Once-Daily Single-Inhaler Triple Therapy for Patients with Chronic Obstructive Pulmonary Disease (COPD) Using the FULFIL Trial: A Spanish Perspective. <i>International Journal of COPD</i> , <b>2020</b> , 15, 1621-1632	3	2
2	Economic evaluations of chronic obstructive pulmonary disease pharmacotherapy: how well are the real-world issues of medication adherence, comorbidities and adverse drug-reactions addressed?. <i>Expert Opinion on Pharmacotherapy</i> , <b>2021</b> , 22, 923-935	4	2
1	Novedades en la clasificaci3n, diagn3stico y tratamiento de la EPOC. <i>FMC Formacion Medica Continuada En Atencion Primaria</i> , <b>2019</b> , 26, 532-547	0	